CD8A and neoplasm: Next, our data support the use and continued investigation of combination therapies with PD-1 pathway blockade to enhance rescue of exhausted, tumor-specific CD8+ T cells by targeting additional inhibitory molecules expressed on BrM-infiltrating terminally differentiated CD8+ T cells, such as CTLA-4 and LAG3.62